Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 2026

Contributed by: Business Wire

Logo

Tags

Health

Consumer

Women

Clinical Trials

Pharmaceutical

Biotechnology

SB16

More Like This

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Samsung Bioepis office in Songdo, Incheon, Republic of Korea

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe

Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results